BRAF and melanoma: Following recent observations from clinical trials indicating that patients with BRAF-mutant melanoma in particular benefit from dual ICI1–3, we wondered whether we could derive a molecular rationale that prospectively leads to a more general biomarker concept for ICI therapy stratification.